Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Isconova AB
Uppsala, Uppsala County, Swedenisconova.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Isconova developed proprietary nano-particle-based adjuvant technologies that enhance the efficacy of vaccines. Its Matrix-M™ adjuvant was used in several clinical-stage vaccine candidates and is commercially available in veterinary products. The company had multiple partnerships with leading pharma/biotech firms and academic groups. In 2013 it was acquired by Novavax Inc., which integrated its platform into Novavax’s pipeline[2][5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccine adjuvants (not direct therapeutics, but enabling technology for vaccines)Nano-particle based adjuvants (Matrix-M™, ISCOM, Posintro™)
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Isconova AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Isconova AB.